WO2020197041A1 - Compositions injectables et cosmétiques comprenant un extrait de mélisse-citronnelle en tant que principe actif - Google Patents

Compositions injectables et cosmétiques comprenant un extrait de mélisse-citronnelle en tant que principe actif Download PDF

Info

Publication number
WO2020197041A1
WO2020197041A1 PCT/KR2019/017047 KR2019017047W WO2020197041A1 WO 2020197041 A1 WO2020197041 A1 WO 2020197041A1 KR 2019017047 W KR2019017047 W KR 2019017047W WO 2020197041 A1 WO2020197041 A1 WO 2020197041A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
weight
lemon balm
composition
active ingredient
Prior art date
Application number
PCT/KR2019/017047
Other languages
English (en)
Korean (ko)
Inventor
임재선
Original Assignee
임재선
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190033690A external-priority patent/KR102036186B1/ko
Priority claimed from KR1020190050030A external-priority patent/KR102027827B1/ko
Application filed by 임재선 filed Critical 임재선
Publication of WO2020197041A1 publication Critical patent/WO2020197041A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9706—Algae
    • A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Definitions

  • the present invention relates to an injection and cosmetic composition
  • a lemon balm extract as an active ingredient.
  • PPC phosphatidylcholine
  • sodium deoxycholate complex injections using phosphatidylcholine (PPC) and sodium deoxycholate have been widely used for local obesity for the purpose of lipoplasty.
  • Cosmeceutical is a compound word of cosmetics and pharmaceuticals, and means medicinal cosmetics. It is a product that combines pharmaceutical ingredients with proven efficacy into cosmetics. Cosmetics in which medical experts such as doctors and pharmacists participated in research and development are also included in the cosmeceutical. If existing cosmetics are for skin care, cosmeceutical products are focused on skin treatment.
  • the present invention is to solve the problems of the prior art described above, and an object of the present invention is to provide an injection composition that makes the face slimmer easily only by injection.
  • An object of the present invention is to provide a cosmetic composition that can be applied to the skin to directly decompose fat in fat cells and exhibit a cellulite removal effect.
  • an injection composition for fat decomposition using lemon balm extract as an active ingredient there is provided an injection composition for fat decomposition using lemon balm extract as an active ingredient.
  • lemon balm extract including lemon balm extract, Maronier (Aesculus Hippocastanum) extract, Fucus Vesiculosus extract, walnut (JuglansRegia) extract, ADP (Disodium Adenosine Phosphate), Adenosine Triphosphate, Tyrosine.
  • Lemon balm extract including lemon balm extract, Maronier (Aesculus Hippocastanum) extract, Fucus Vesiculosus extract, walnut (JuglansRegia) extract, ADP (Disodium Adenosine Phosphate), Adenosine Triphosphate, Tyrosine.
  • an injection composition for decomposing fat containing the composition as an active ingredient.
  • the composition provides a cosmetic composition comprising lemon balm extract as an active ingredient, which is applied to the skin by an ultrasonic device, a high-frequency device, an electroporation, or a needleless injection.
  • a cosmetic composition that uses lemon balm extract as an active ingredient to decompose fat in an area to be applied and remove cellulite.
  • 1 is a graph showing the clinical results of an injection composition according to the practice of the present invention.
  • FIG. 2 is an enlarged photograph showing a tissue in which adipocytes are distributed before the injection composition is injected into adipocytes according to an embodiment of the present invention.
  • FIG. 3 is an enlarged photograph showing a tissue in which fat cells are reduced by 80% after injection of an injection composition according to an embodiment of the present invention.
  • 4 and 5 show photographs before and after performing a procedure using an injection composition according to an embodiment of the present invention for 4 weeks.
  • 6 and 7 are graphs showing clinical results of a cosmetic composition according to an embodiment of the present invention.
  • composition for lipolysis comprising lemon balm extract according to an embodiment of the present invention as an active ingredient may be administered subcutaneously as an injection or applied as a cosmetic composition for lipolysis, lymph circulation, V-line face, and elastic face.
  • composition according to an embodiment of the present invention may be administered to correct facial lines through fat decomposition by injection into areas such as crow's feet, cheeks, cheekbones, lip fat, chin line, and double chin. It is an effective composition that enables delicate sculpting according to the condition of the individual's face. It relieves edema, breaks down fat, promotes lymph circulation, and has anti-cellulite action.
  • compositions for fat decomposition include lemon balm extract, Maronier (Aesculus Hippocastanum) extract, Fucus Vesiculosus extract, walnut (JuglansRegia) extract, ADP (Disodium Adenosine Phosphate), Adenosine Triphosphate , It is preferable to include Tyrosine.
  • the lipolytic injection composition according to the first embodiment of the present invention is preferably composed of the following components.
  • Table 1 is a table showing the components and mixing ratios of the injection composition according to the first embodiment of the present invention. Numbers represent weight percent.
  • Lemon balm (Melissa officinalis) is a plant belonging to the Lamiaceae family (Labiatae), a variety of active flavonoids (cynaroside (cynaroside), cosmosin (cosmosin), rhamnocitrin (rhamnocitrin), isoquercitrin (isoquercitrin)), terpenes and It is known to contain triterpene acids (ursolic acid and oleanolic acid) (Herodez SS, Hadolin M, Skerget M, Knez Z Solvent extraction study of antioxidants from balm (Melissa officinalis L).
  • Lemon balm extract is Melissa officinalis leaf extract, which grows naturally in the Mediterranean coast and in the middle of the Mediterranean Sea. It is also called “Melissa”. It has a lemon-like scent and contains rich rosmarinic acid. Rosmarinic acid helps diet, antioxidant and anti-inflammatory properties.
  • Lemon balm extract is a polyphenol and tannin ingredient that has excellent skin protection.
  • Lemon balm extract is a polar solvent selected from the group consisting of water, methanol, ethanol, and a mixture of two or more thereof, preferably water, to extract lemon balm outpost, preferably lemon balm leaves, and spray-dry to powder .
  • Aesculus HIPPOCASTANUM HORSE CHESTNUT SEED EXTRAC, also known as Maronie seed extract, has anti-edema effect, anti-inflammatory effect, prevents edema formation on the walls of vascular tissue, reduces acute symptoms, and protects the skin from UV rays. It prevents the skin and has the effect of preventing rough skin.
  • Walnut extract JUGLANS REGIA (WALNUT) SEED EXTRACT
  • WALNUT WEBUT SEED EXTRACT
  • Bladder Lac Extract (FUCUS VESICULOSUS EXTRACT) is an ingredient extracted from large brown algae seaweed, and contains a large amount of minerals, vitamins, and amino acids, so it has the effect of protecting and hydrating the skin and moisturizing rough and dry skin. It absorbs fat and helps in discharging waste products.
  • Sodium Chloride is an inorganic salt component that is a compound of sodium (sodium) and chloride (chloride) and is used as an acidity regulator, preservative function, flavor, and viscosity enhancer in cosmetics and beauty products.
  • Propylene Glycol is a component obtained by hydrolyzing propylene oxide. It has a small molecular weight and has excellent skin penetrability, so it is used for penetration of active ingredients. It has the effect of improving skin moisturizing power by maintaining moisture in the skin.
  • Phenoxyethanol is an ingredient that combines phenol and ethylene glycol. It is an ingredient that mainly acts as a preservative and retention agent in cosmetics.It is one of the alternative preservatives used in cosmetics to replace paraben, which was once notorious for breast cancer.
  • Methylpropanediol is a type of glycol used as a solvent. It helps various ingredients (such as salicylic acid) to penetrate the skin. It has hydrating properties and helps to soften and moisturize the skin.
  • Tyrosine is a skin amino acid that starts the production of melanin. It is a precursor of catecholamine in the body and thyroxine, a thyroid hormone, and promotes fat metabolism.
  • Ethylhexylglycerin is a glyceryl ether, an organic compound component, and is a kind of glycerin. It is a kind of wetting agent with softness, wetting agent and proper spreading performance.
  • preservatives such as phenoxyethanol, isothiazolinone, and parabens
  • the amount of preservatives used can be reduced. It has a deodorizing effect by inhibiting the growth of bacteria and gives skin conditioning.
  • METHYLSILANOL MANNURONATE is a material that combines silanol, an organic silicon (SI), and Mannuronic Acid, which is derived from alginic acid of brown algae, and rejuvenates skin, strengthens elasticity, and stretch marks. It has anti-oxidation, lipolysis, and moisturizing effects.
  • SORBIC ACID is an ingredient present in berries such as blueberries, and has the effect of inhibiting the growth of microorganisms such as bacteria and fungi, so it is mainly used as an antiseptic ingredient in all cosmetics. It is an ingredient that is allowed not only in cosmetics but also in food.
  • Adenosine Phosphate (ADENOSINE PHOSPHATE) is a complex, anti-wrinkle, anti-inflammatory, sedative, and cell-communicating ingredient that delivers activated oxygen to skin cells in the dermis layer, and promotes collagen synthesis by enhancing the size and proliferation of fibroblasts.
  • Disodium adenosine triphosphate (DISODIUM ADENOSINE TRIPHOSPHATE) is a component of the disodium salt of adenosine triphosphate. It is used to impart conditioning to the skin.
  • the nasolabial folds appear deep because of the cheeks next to the nasolabial folds, if there is a lot of fat such as cheeks or double chins, Botox If the square jaw cannot be corrected by itself, if the facial line is not corrected even after contouring or double jaw surgery, if you are afraid of liposuction or surgery, if fat transplantation is excessive, before/after lifting, facial asymmetry patients, existing lipolytic drugs If it is not effective, target patients who want a slim face without affecting their daily life in a short time.
  • the patient's age is for male and female patients over 20 years old. This is the result after 4 times a month treatment once a week.
  • a 32G needle (1cc syringe) and Mesogun were used.
  • Lemon balm composition solution divided into 3-4 points per 1cc and injected subcutaneously (SQ level). After the procedure, gently massage, antibiotic ointment or Vit. K ointment is applied.
  • Table 2 is a table showing the number of procedures, doses, and intervals for each treatment site.
  • FIGS. 2 and 3 show electron micrographs showing an experiment in which a composition according to an embodiment of the present invention reacts to adipocytes.
  • 2 is a picture before the composition is injected
  • Figure 3 is a picture after the composition is injected. It can be seen that the red circle represents fat cells and about 80% of fat cells have been reduced.
  • 4 and 5 show photographs before and after performing a procedure using an injection composition according to an embodiment of the present invention for 4 weeks, respectively. As shown, a dramatic change in facial line can be confirmed by the decomposition of fat and cellulite in 4 weeks.
  • the cosmetic composition for lipolysis comprising lemon balm extract according to an embodiment of the present invention as an active ingredient may be applied as a cosmetic composition for lipolysis, lymph circulation, V-line face, and elastic face.
  • the lipolysis composition according to an embodiment of the present invention is a lemon balm extract, a maronier (Aesculus Hippocastanum) extract, a Fucus Vesiculosus extract, a walnut (JuglansRegia) extract, ADP (Disodium Adenosine Phosphate), Adenosine Triphosphate, Tyrosine It is preferable to include.
  • the cosmetic composition for fat decomposition according to the second embodiment of the present invention is preferably composed of the following ingredients.
  • INGREDIENT (ICID) weight% AQUA Purified water 99.01937 SODIUM CHLORIDE Sodium chloride 0.898 MELISSA OFFICINALIS LEAF EXTRACT Lemon Balm Extract 0.01875 AESCULUS HIPPOCASTANUM (HORSECHESTNUT) SEED EXTRACT Spiny leaves seed extract 0.0056 JUGLANS REGIA (WALNUT) SEED EXTRACT Walnut extract 0.0056 TYROSINE Tyrosine 0.008 FUCUS VESICULOSUS EXTRACT Bladder Rack Extract 0.0024 ADENOSINE PHOSPHATE Adenosine phosphate 0.00024 DISODIUM ADENOSINE TRIPHOSPHATE Disodium adenosine triphosphate 0.00024 METHYLPROPANEDIOL Methylpropanediol 0.04 METHYLSILANOL MANNURONATE Methylsilanolmannuronate 0.0018
  • Table 3 is a table showing the components and blending ratios of the cosmetic composition for decomposing fat according to the second embodiment of the present invention. Numbers represent weight percent.
  • Lemon balm extract is a polar solvent selected from the group consisting of water, methanol, ethanol, and a mixture of two or more thereof, preferably water, to extract lemon balm outpost, preferably lemon balm leaves, and spray-dry to powder .
  • the effect of reducing fat and cellulite was used when lemon balm extract was applied to the skin.
  • the recipients were classified by the type of cellulite of the recipient as shown in Table 4 below.
  • the age of the recipient was as follows. 70% of the patients were 15 to 35 years old.
  • Electroporation was applied to the entire treatment area including the peritrochanteric ( ⁇ ) and the inside of the knee, and the following results were obtained. Electroporation, which means electroporation, is more effective in absorbing a formula such as the composition according to an embodiment of the present invention because it temporarily opens the skin lipid by applying an electric pulse to the skin lipid.
  • the clinical trial was conducted once a week over a period of 4-10 weeks depending on the patient's condition. After that, it was conducted once every other week, a total of two times, and after the two times, it was conducted only once a month for "maintenance purposes".
  • the time per session ranged from a minimum of 30 minutes to a maximum of 40 minutes, and the power level was 75 to 90%. Be careful that you massage the applied area in a gentle circular motion. Excluding the "maintenance" procedure, 71% of the patients who received 5 to 10 treatments, 25% of the patients who received 11 to 20 treatments, including the "maintenance" procedure, and those who received more than 21 times It was 4%.
  • 6 is a graph showing the reduction width of the peritrochanteric ( ⁇ ) diameter. 21% showed 2cm, 46% 3cm, and 21% 4cm reduction effect.
  • FIG. 7 is a table showing the comprehensive evaluation of the subjects to be treated. Subjective evaluation of the procedure was made, and the evaluation criteria included not only changes in body weight, but also the degree of syndrome (side effects) that may appear during the procedure and rapid return to daily life.
  • vagus nerve vagal, ⁇

Abstract

La présente invention concerne : une composition cosmétique comprenant un extrait de mélisse-citronnelle ayant un effet lipolytique, de l'eau purifiée, du chlorure de sodium, un extrait de graine d'Aesculus hippocastanum, un extrait de Juglans regia, de la tyrosine, un extrait de Fucus vésiculosus, de l'adénosine phosphate, du méthylpropanediol, et du méthylsilanol mannuronate ; et une composition injectable comprenant un extrait de mélisse-citronnelle, un extrait d'Aesculus hippocastanum, un extrait de Fucus vesiculosus, un extrait de Juglans regia, du phosphate d'adénosine disodique (ADP), de l'adénosine triphosphate, et de la tyrosine.
PCT/KR2019/017047 2019-03-25 2019-12-04 Compositions injectables et cosmétiques comprenant un extrait de mélisse-citronnelle en tant que principe actif WO2020197041A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020190033690A KR102036186B1 (ko) 2019-03-25 2019-03-25 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 주사제 조성물
KR10-2019-0033690 2019-03-25
KR10-2019-0050030 2019-04-29
KR1020190050030A KR102027827B1 (ko) 2019-04-29 2019-04-29 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 화장료 조성물

Publications (1)

Publication Number Publication Date
WO2020197041A1 true WO2020197041A1 (fr) 2020-10-01

Family

ID=72611582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/017047 WO2020197041A1 (fr) 2019-03-25 2019-12-04 Compositions injectables et cosmétiques comprenant un extrait de mélisse-citronnelle en tant que principe actif

Country Status (3)

Country Link
JP (1) JP6943941B2 (fr)
CN (1) CN111728903B (fr)
WO (1) WO2020197041A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100645385B1 (ko) * 2005-10-05 2006-11-23 주식회사 안지오랩 비만 억제용 조성물
JP2007091645A (ja) * 2005-09-29 2007-04-12 Ichimaru Pharcos Co Ltd ニーム抽出物を含有する抗肥満用飲食品
KR20120086436A (ko) * 2011-01-26 2012-08-03 주식회사 코스메카코리아 슬리밍 화장료 조성물
KR20130133285A (ko) * 2012-01-23 2013-12-06 레스토시, 엘엘씨 화장품
KR102027827B1 (ko) * 2019-04-29 2019-10-02 임재선 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 화장료 조성물
KR102036186B1 (ko) * 2019-03-25 2019-10-24 임재선 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 주사제 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5081203B2 (ja) * 2003-07-29 2012-11-28 花王株式会社 脂肪分解促進剤
JP2008074814A (ja) * 2006-09-25 2008-04-03 Nivea Kao Kk 脂肪分解促進剤
RS20100392A3 (en) * 2010-09-06 2012-12-31 Pavlov, Aleksandar PROCEDURE FOR OBTAINING A HERBAL PREPARATION BASED ON AN EXTRACT OF A HERBAL MIXTURE FOR APPLICATION TO THE SKIN AND A HERBAL PREPARATION OBTAINED BY THIS PROCEDURE
CN107149582A (zh) * 2017-05-13 2017-09-12 佛山文森特知识产权服务有限公司 一种抗衰老组合物及其应用
KR101825171B1 (ko) * 2017-07-31 2018-02-02 이충녕 가슴 확대 및 피부 탄력 향상용 화장료 조성물
CN108125892A (zh) * 2017-12-11 2018-06-08 百朗德生物化学(海门)有限公司 一种海洋生物保湿抗衰老化妆品组合物
CN108309834A (zh) * 2018-04-19 2018-07-24 广州赛莱拉干细胞科技股份有限公司 基于褐藻提取物的护肤组合物
CN109464452A (zh) * 2018-12-28 2019-03-15 广州涵夏基因健康科技有限公司 三磷酸腺苷盐在制备外用消脂减肥产品中的应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007091645A (ja) * 2005-09-29 2007-04-12 Ichimaru Pharcos Co Ltd ニーム抽出物を含有する抗肥満用飲食品
KR100645385B1 (ko) * 2005-10-05 2006-11-23 주식회사 안지오랩 비만 억제용 조성물
KR20120086436A (ko) * 2011-01-26 2012-08-03 주식회사 코스메카코리아 슬리밍 화장료 조성물
KR20130133285A (ko) * 2012-01-23 2013-12-06 레스토시, 엘엘씨 화장품
KR102036186B1 (ko) * 2019-03-25 2019-10-24 임재선 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 주사제 조성물
KR102027827B1 (ko) * 2019-04-29 2019-10-02 임재선 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 화장료 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Lemon balm, from fat breakdown to menstrual pain relief... Efficacy `great`", MK CO, 13 April 2019 (2019-04-13), pages 1 - 4, XP055743504, Retrieved from the Internet <URL:https://www.mk.co.kr/news/it/view/2019/04/228191> *

Also Published As

Publication number Publication date
CN111728903A (zh) 2020-10-02
JP2020158484A (ja) 2020-10-01
JP6943941B2 (ja) 2021-10-06
CN111728903B (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
US11571452B2 (en) Method of treating a skin wound with a liquid-state topical pharmaceutical composition
CN106074206B (zh) 一种护肤主剂、制备方法及其应用
CN1466461A (zh) 止痒性组合物和促进创伤治愈的组合物
CN101836944B (zh) 植物提取物的组合物及对皮肤美白保湿的应用
CN103211730B (zh) 一种由天然中草药制成的美容精华液及其制备方法
CN108452275A (zh) 一种具有舒筋活络功效的组合物、药剂及制备方法
KR102027827B1 (ko) 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 화장료 조성물
CN102228485A (zh) 用于烧伤康复的组合物及其制备方法
CN108938759B (zh) 一种治疗手足综合征的药物或者日化用品组合物及其制备方法和用途
US20140348873A1 (en) Urea-Silicone Gel for Hyperkeratosis Treatment
CN102784299A (zh) 促进伤口愈合不留瘢痕色素的外用膏及其制备方法
KR102036186B1 (ko) 레몬밤 추출물을 유효성분으로 포함하는 지방 분해용 주사제 조성물
US20190216871A1 (en) Diabetic foot cream
CN107441340B (zh) 一种消肿止痛止痒滋养皮肤的手足皴裂膏及其制备方法
WO2020197041A1 (fr) Compositions injectables et cosmétiques comprenant un extrait de mélisse-citronnelle en tant que principe actif
US11154583B2 (en) Composition and method of skin relief cream useful for eczema, psoriasis, lipoma, burn wounds, scars, keloids, shingles, dry skin disorders, and skin allergies
US20160106798A1 (en) Topical treatment for use in conjunction with acupuncture or acupressure therapy
CN107375613A (zh) 一种具有袪除面部红血丝功效的中药提取物及其外用制剂
CN102847030A (zh) 一种祛斑面膜
CN106727051A (zh) 一种中药祛痘精华及其制备方法
US9421235B2 (en) Medicine containing extracts of Ficus microcarpa for healing wounds of a diabetic patient
CN110812377A (zh) 一种痤疮治疗修复组合物及其应用
RU2369377C1 (ru) Фитобальзам для регенерации кожи &#34;инсофит&#34;
CN110269926A (zh) 温中舒暖组合物及其制备方法和应用
CN108653431A (zh) 防治鼻炎的药物组合物、制备方法及其应用和制剂

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19922132

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19922132

Country of ref document: EP

Kind code of ref document: A1